Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Precision Medicine for NSCLC in the Era of Immunotherapy: New Biomarkers to Select the Most Suitable Treatment or the Most Suitable Patient
Giovanni Rossi, Alessandro Russo, Marco Tagliamento, et al.
Cancers (2020) Vol. 12, Iss. 5, pp. 1125-1125
Open Access | Times Cited: 59

Showing 1-25 of 59 citing articles:

TMB or not TMB as a biomarker: That is the question
Alfredo Addeo, Alex Friedlaender, Giuseppe Luigi Banna, et al.
Critical Reviews in Oncology/Hematology (2021) Vol. 163, pp. 103374-103374
Closed Access | Times Cited: 177
Cancer immunotherapy with immune checkpoint inhibitors (ICIs): potential, mechanisms of resistance, and strategies for reinvigorating T cell responsiveness when resistance is acquired
Hany E. Marei, Anwarul Hasan, Giacomo Pozzoli, et al.
Cancer Cell International (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 114
The prognostic impact of tumor mutational burden (TMB) in the first-line management of advanced non-oncogene addicted non-small-cell lung cancer (NSCLC): a systematic review and meta-analysis of randomized controlled trials
Antonio Galvano, Valerio Gristina, Umberto Malapelle, et al.
ESMO Open (2021) Vol. 6, Iss. 3, pp. 100124-100124
Open Access | Times Cited: 105
Review of the Immune Checkpoint Inhibitors in the Context of Cancer Treatment
Norah A. Alturki
Journal of Clinical Medicine (2023) Vol. 12, Iss. 13, pp. 4301-4301
Open Access | Times Cited: 57
Immunoscore immune checkpoint using spatial quantitative analysis of CD8 and PD-L1 markers is predictive of the efficacy of anti- PD1/PD-L1 immunotherapy in non-small cell lung cancer
François Ghiringhelli, Frédéric Bibeau, Laurent Greillier, et al.
EBioMedicine (2023) Vol. 92, pp. 104633-104633
Open Access | Times Cited: 45
Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target
Wenjing Qian, Mingfang Zhao, Ruoyu Wang, et al.
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 79
Immunotherapy in nonsmall-cell lung cancer: current status and future prospects for liquid biopsy
Elena Brozos-Vázquez, Roberto Díaz‐Peña, Jorge García, et al.
Cancer Immunology Immunotherapy (2020) Vol. 70, Iss. 5, pp. 1177-1188
Closed Access | Times Cited: 75
First-Line Immune-Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Landscape and Future Progress
Zhangfeng Huang, Wenhao Su, Tong Lü, et al.
Frontiers in Pharmacology (2020) Vol. 11
Open Access | Times Cited: 67
VISTA: A Promising Target for Cancer Immunotherapy?
Marco Tagliamento, Elisa Agostinetto, Roberto Borea, et al.
ImmunoTargets and Therapy (2021) Vol. Volume 10, pp. 185-200
Open Access | Times Cited: 46
Systematic pan-cancer analysis of mutation–treatment interactions using large real-world clinicogenomics data
Ruishan Liu, Shemra Rizzo, Sarah Waliany, et al.
Nature Medicine (2022) Vol. 28, Iss. 8, pp. 1656-1661
Closed Access | Times Cited: 38
Subunits of ARID1 serve as novel biomarkers for the sensitivity to immune checkpoint inhibitors and prognosis of advanced non-small cell lung cancer
Dantong Sun, Tian Lu, Yan Zhu, et al.
Molecular Medicine (2020) Vol. 26, Iss. 1
Open Access | Times Cited: 42
Therapeutic Implications of PTEN in Non-Small Cell Lung Cancer
Zaid Sirhan, Rawan Alojair, Anita Thyagarajan, et al.
Pharmaceutics (2023) Vol. 15, Iss. 8, pp. 2090-2090
Open Access | Times Cited: 14
Extracellular vesicles miR-574-5p and miR-181a-5p as prognostic markers in NSCLC patients treated with nivolumab
Carlo Genova, Silvia Marconi, Giovanna Chiorino, et al.
Clinical and Experimental Medicine (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 5
Immunotherapy in non-small cell lung cancer: rationale, recent advances and future perspectives
Wenxin Luo, Zhoufeng Wang, Ting Zhang, et al.
Precision Clinical Medicine (2021) Vol. 4, Iss. 4, pp. 258-270
Open Access | Times Cited: 28
Predictive value of tumor mutational burden for immunotherapy in non-small cell lung cancer: A systematic review and meta-analysis
Guangxian Meng, Xiaowei Liu, Tian Ma, et al.
PLoS ONE (2022) Vol. 17, Iss. 2, pp. e0263629-e0263629
Open Access | Times Cited: 21
Impact of probiotics use on clinical outcomes of immune checkpoint inhibitors therapy in cancer patients
Luying Wan, Chunlan Wu, Qin Wu, et al.
Cancer Medicine (2022) Vol. 12, Iss. 2, pp. 1841-1849
Open Access | Times Cited: 21
Immunotherapy-chemotherapy combinations for non-small cell lung cancer: current trends and future perspectives
Eugenia Cella, Lodovica Zullo, Silvia Marconi, et al.
Expert Opinion on Biological Therapy (2022) Vol. 22, Iss. 10, pp. 1259-1273
Closed Access | Times Cited: 20
LRP1B mutation is associated with tumor immune microenvironment and progression-free survival in lung adenocarcinoma treated with immune checkpoint inhibitors
Ziyi He, Wei Feng, Yuxuan Wang, et al.
Translational Lung Cancer Research (2023) Vol. 12, Iss. 3, pp. 510-529
Open Access | Times Cited: 12
Navigating the landscape of PD-1/PD-L1 imaging tracers: from challenges to opportunities
Melinda Badenhorst, Albert D. Windhorst, Wissam Beaino
Frontiers in Medicine (2024) Vol. 11
Open Access | Times Cited: 4
Testing Cancer Immunotherapy in a Human Immune System Mouse Model: Correlating Treatment Responses to Human Chimerism, Therapeutic Variables and Immune Cell Phenotypes
Juan A. Marín‐Jiménez, Anna Capasso, Matthew S. Lewis, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 26
Anti-PD-(L)1 immunotherapy for brain metastases in non-small cell lung cancer: Mechanisms, advances, and challenges
Yingtang Zhou, Jingjing Xie, Zhaoqin Huang, et al.
Cancer Letters (2021) Vol. 502, pp. 166-179
Closed Access | Times Cited: 25
Platelet‑to‑lymphocyte and neutrophil‑to‑lymphocyte ratios are associated with the efficacy of immunotherapy in stage III/IV non‑small cell lung cancer
Xiaojuan Lu, Junyan Wan, Huaqiu Shi
Oncology Letters (2022) Vol. 24, Iss. 2
Open Access | Times Cited: 18
Prognostic and Immunological Role of FAT Family Genes in Non-Small Cell Lung Cancer
Zhenxing Feng, Yan Yin, Bin Liu, et al.
Cancer Control (2022) Vol. 29
Open Access | Times Cited: 17
Prognostic significance of programmed cell death ligand 1 blood markers in non-small cell lung cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis
Ningning Zhang, Jianlan Chang, Ping Liu, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 3
Serum immune mediators as novel predictors of response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients with high tissue-PD-L1 expression
Afsheen Raza, Reyad Mohsen, Aladdin Kanbour, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 9
Page 1 - Next Page

Scroll to top